Reich K, Langley RG, Salvador JFS, Staumont-Salle D, et al. Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of 8 clinical trials. Br J Dermatol 2025 Aug 29:ljaf309. doi: 10.1093.
PMID: 40879371